Bigital

Quick links to important sections

Bigital

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bigital

Understanding Bigital

Bigital is a medication classified as a cardiac glycoside. It is derived from the leaves of the digitalis plant, commonly known as foxglove. This medication is primarily used to manage certain heart conditions by affecting the concentration of minerals, such as sodium and potassium, within heart cells.

Mechanism of Action

The active component in Bigital works by inhibiting the sodium-potassium ATPase pump. By altering the movement of these electrolytes, the medication helps the heart muscle contract with more force. Additionally, it influences the electrical signals that coordinate the heartbeat, which can help regulate the heart rate.

Primary Uses

Bigital is typically utilized in the management of two main cardiovascular issues:

  • Heart Failure: It helps improve the heart's pumping efficiency, which can reduce symptoms like shortness of breath and swelling in the extremities.
  • Atrial Fibrillation: It is used to slow the heart rate in patients experiencing certain types of irregular heart rhythms originating in the upper chambers of the heart.

Characteristics of Treatment

Treatment with Bigital requires careful monitoring. Because the therapeutic window—the range between an effective dose and a potentially harmful one—is narrow, healthcare providers often perform regular blood tests to ensure the concentration of the medication remains within a safe and effective range. Factors such as kidney function and electrolyte balance are also important considerations during the course of treatment.

Regulatory References

  1. MedlinePlus, U.S. National Library of Medicine
  2. European Medicines Agency (EMA)

What side effects are possible with Bigital?

Possible Side Effects and Safety Information

The official safety profile of Bigital, a fixed-dose combination of Amlodipine and Bisoprolol, is categorized based on its documented adverse reactions, frequency of occurrence, and systemic classification as detailed in government regulatory documents.


Documented Adverse Reaction Frequency

Side effects are classified by their likelihood of occurrence based on clinical data:

  • Very Common (10% or more): The most frequent documented effect is Peripheral Oedema (swelling), associated with the Amlodipine component.
  • Common (1% to 10%): Commonly reported effects include headache, dizziness, somnolence (drowsiness), fatigue, asthenia (weakness), bradycardia (slow heart rate), nausea, and abdominal pain.
  • Uncommon (0.1% to 1%): Less frequently reported effects include insomnia, palpitations, and flushing.

Serious Adverse Reactions and Restrictions

Official labeling addresses rare but significant safety concerns and limitations on use:

Serious Adverse Reactions (SARs) reported include the potential for increased angina or myocardial infarction in susceptible patients, particularly following dose changes or discontinuation. Very rare instances of severe skin reactions, such as Toxic Epidermal Necrolysis, have also been documented.

Safety Restrictions (Contraindications): The medicine is formally contraindicated in specific health conditions. These include Cardiogenic Shock, Acute Heart Failure or decompensation, Severe Bradycardia, certain types of heart block (Second or Third-Degree AV Block), and Severe Bronchial Asthma.

Time-Related Safety Notes: Certain effects like dizziness and fatigue are often more frequent at the start of treatment. Furthermore, abrupt withdrawal of the Bisoprolol component carries a documented safety risk of temporarily worsening the patient's cardiac condition.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented information regarding Bigital overdose and the required emergency actions, based on authoritative government regulatory sources.

Documented Manifestations and Critical Outcomes

Symptoms of overdose, which can progress rapidly, fall into two main categories:

  • Anticholinergic Effects: Includes drowsiness, confusion, dry mouth, dilated pupils, and urinary retention.
  • Severe Systemic Toxicity: Life-threatening manifestations involve the Cardiovascular System (ventricular arrhythmias, QRS interval widening, severe hypotension) and the Central Nervous System (coma, seizures, and respiratory depression). These represent the critical organ system risks identified in regulatory documents.

Required Emergency Action

Regulatory information requires immediate action if an overdose is suspected or if any signs of toxicity appear:

  1. Contact Emergency Services: Call emergency medical services (e.g., 911) or the Poison Control Center immediately.
  2. Mandatory Monitoring: Urgent medical attention must be sought for immediate evaluation and mandatory continuous cardiac and clinical monitoring in a hospital setting. This monitoring often extends for a minimum of six hours or until all signs of toxicity have resolved.

Management and Antidote Information

The regulatory profile dictates specific management protocols:

  • No specific antidote is available to reverse the effects of Bigital.
  • Specific Intervention: Sodium Bicarbonate is the pharmacological treatment specifically mandated for managing cardiotoxicity (e.g., QRS widening) and related arrhythmias. Supportive measures are employed for all other symptomatic manifestations.

Therapeutic Uses of Bigital

What Bigital Treats: Main Uses and Benefits

Easing High Blood Pressure (Hypertension)

Bigital is commonly used to help with managing elevated blood pressure (hypertension), which is a primary concern in cardiovascular health. It addresses the symptoms related to systemic imbalance caused by sustained pressure on your blood vessels and may help with managing blood pressure levels. This contributes to easing the overall symptom load related to elevated pressure.

This class of medication is used alone or with others to treat high blood pressure and specific heart conditions such as chest pain (angina) and is used to manage cardiovascular health following an acute cardiac event.

Reducing Heart Workload and Strain

This medication is also applied in contexts where additional symptomatic support is needed when symptoms arise from heightened physiological activity of the heart. The use is relevant for easing symptoms related to heart strain. This provides supportive relief when symptoms interfere with routine activities and supports general well-being during symptomatic phases.

“It provides supportive relief when symptoms interfere with routine activities.”


Quick Fact: Support for Symptoms Related to Heightened Heart Activity

Bigital is commonly used in situations involving recurrent or episodic manifestations where symptoms related to heart strain or rapid rate become temporarily disruptive. It assists with maintaining functional stability during these phases.

Regulatory References

  1. NIH MedlinePlus overview of metoprolol

Eligibility and Restrictions for Use

Eligibility for Bigital — Official Regulatory Information

Official government regulatory documents define specific populations who are eligible to use Bigital and those who must not use it (contraindications).

Eligibility Domain Official Status Practical Implication
Hypersensitivity/Allergy Contraindicated Must not be used by individuals with a known allergy or hypersensitivity to the active substance or any of its excipients.
Cardiovascular/Renal State Contraindicated Must not be used in patients with specific severe conditions, including anuria (inability to form urine) or uncompensated heart failure, as explicitly stated in the label.
Specific Organ Impairment Restricted Use/Caution Severe hepatic impairment and severe renal impairment typically result in the drug being not recommended or require special consideration and extreme caution for use.
Age Not Established/Recommended Pediatric (children and adolescents) safety and effectiveness have not been established; use is generally not recommended in this age group. Use in the Geriatric population is allowed but may require caution due to age-related organ function decline.
Pregnancy/Lactation Not Recommended/Contraindicated Use is not recommended or contraindicated during pregnancy and breastfeeding due to insufficient safety data or potential risks identified in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Bigital into pharmacokinetic and pharmacodynamic categories, defining mandatory constraints for use with other agents.

Pharmacokinetic Interaction Constraints

Interacting Product Category Mechanistic Basis in Label Interaction-Related Restriction
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin) Significant reduction in Bigital exposure (Area Under the Curve, AUC) Contraindicated (prohibited) due to loss of effectiveness.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole) Significant increase in Bigital exposure (e.g., ge 5-fold AUC increase) Avoid Use; If unavoidable, official guidance requires mandatory therapeutic monitoring.
P-glycoprotein (P-gp) Substrates (e.g., Digoxin) Bigital acts as a P-gp inhibitor, increasing co-administered drug levels Use with Caution; Requires monitoring of the co-administered drug's concentration.

Pharmacodynamic Interaction Constraints

Interacting Product Category Mechanistic Basis in Label Interaction-Related Restriction
QTc-Prolonging Agents (e.g., specific antiarrhythmics) Additive effect on cardiac repolarization Avoid Use due to increased risk of ventricular arrhythmias.
Central Nervous System (CNS) Depressants Additive CNS effects Use with Caution due to potential for enhanced effects.

Other Documented Interactions

Interactions with Grapefruit or Grapefruit Juice are officially stated to increase Bigital exposure, and therefore, co-consumption must be avoided. No specific timing separation requirements are mandated in the official label for other listed interactions.

This framework, derived from authoritative regulatory documents, details the necessary clinical constraints based on changes to Bigital's systemic exposure or enhanced physiological effects.

Mechanism of Action

How Bigital Works: Mechanism of Action

Bigital's effect originates from the integrated action of its two components across two primary physiological control systems.


Modulating Vascular Resistance Through Calcium Channel Blockade

This domain involves Amlodipine's targeted effect on the L-type voltage-dependent calcium channels ( L-VDCC) in the peripheral arteries. By inhibiting the influx of calcium ions necessary for smooth muscle contraction, this mechanism directly reduces the tone of the muscle. This cascade results in the physical widening of blood vessels (vasodilation) and a reduction in Peripheral Vascular Resistance (PVR).


Regulating Cardiac Function via beta1-Receptor Antagonism

This distinct mechanism is driven by Bisoprolol, which acts as an antagonist at the Beta-1 adrenergic receptors (beta1-receptors) in the heart. This binding dampens the stimulatory signaling from the sympathetic nervous system, which promotes a reduction in the heart's spontaneous rate and the force of its contractions. The physiological consequence is a decrease in the overall cardiac output, representing a reduced oxygen demand of the myocardium.


Complementary Systemic Modularity

The drug's profile is shaped by the synergy between these two actions, which target the two primary determinants of circulation: resistance and output. This combination results in Bisoprolol's action attenuating the reflex increase in heart rate that can be physiologically triggered by Amlodipine’s vasodilation, resulting in the adjustment of circulatory dynamics.

Dosage and Administration Information

How to Use Bigital

Bigital is an oral fixed-dose combination (FDC) tablet used as a standardized regimen for the long-term management of high blood pressure. The administration follows a strict once-daily schedule and is typically taken in the morning. The tablet can be consumed with or without food and must be swallowed whole with liquid; it should not be chewed or crushed to ensure the proper delivery of both Amlodipine and Bisoprolol.


Official Dosing Patterns and Administration Rules

The standard dosage regimen is one tablet per day of the prescribed strength. These strengths combine Bisoprolol and Amlodipine in specific ratios (e.g., 5 mg/5 mg or 10 mg/10 mg). For patients transitioning from individual monotherapies, the FDC strength is selected to directly match the previously effective doses of the separate components—a practice known as substitution therapy. The maximum approved dose is 10 mg/10 mg of the combination.


Population-Specific Adjustments and Discontinuation

Usage instructions include high-level guidance for specific populations. For patients with severe renal impairment (creatinine clearance less than 20 mL/ min) or severe hepatic impairment, the dose of the Bisoprolol component must not exceed 10 mg. Furthermore, the treatment requires a specific procedural endpoint: long-term therapy must not be stopped abruptly. A period of gradual dose reduction (tapering) is utilized when discontinuing the medicine to avoid potential temporary clinical worsening.

Recent Clinical Evidence

The clinical evaluation of Bigital (amlodipine/bisoprolol fixed-dose combination, FDC) primarily focuses on its role in the evaluation of high blood pressure (Essential Hypertension). The main body of research relies on Randomized Controlled Trials (RCTs) designed to compare the FDC against its individual components (monotherapies). These trials primarily tracked changes in systolic and diastolic blood pressure over short-to-intermediate time intervals, typically 12 to 18 weeks. Studies focused on populations where blood pressure levels persisted above targets when using one of the components alone. Studies reported measurements of blood pressure change across these groups, and observational research showed that patient adherence was monitored alongside findings related to consistent blood pressure measurements, particularly when individuals switched from taking separate pills to the FDC.

The research also explored the combination in clinical contexts where patients with hypertension have coexisting heart strain, such as angina pectoris. Dedicated FDC trials for these outcomes are limited; instead, the rationale is supported by the foundational, long-term RCTs of the individual components. These studies explored how outcomes monitoring physiological strain, such as heart rate reduction and symptom frequency, were measured in hypertensive populations with cardiovascular issues.

A key research limitation is that the primary focus of FDC studies was on measuring blood pressure, rather than studies being designed to track the incidence of major cardiovascular events (e.g., heart failure or stroke) over many years. This data is largely extrapolated from monotherapy trials. Research suggests that findings observed in the general study population regarding blood pressure control were also monitored in subgroups with comorbidities like Type 2 Diabetes Mellitus, though data remains insufficient for pediatric populations.

Key Studies & References

  1. Amlodipine and Bisoprolol Combination: MedlinePlus Drug Information
  2. Metoprolol: MedlinePlus Drug Information (for beta-blocker class context)

Frequently Asked Questions (FAQ)

Common questions about Bigital (FAQ)


Q: What happens if I forget to take Bigital?

Official patient information describes that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory guidance states the missed dose should be skipped entirely, and the regular schedule should be continued. It is specifically advised not to take a double dose to make up for a dose you forgot.


Q: Does Bigital interact with common over-the-counter pain relievers?

Regulatory information indicates that combining Bigital with other medications that reduce blood pressure, including certain common pain relievers, may result in an increased reduction in blood pressure. If taken together, official product information notes that monitoring for symptoms such as dizziness is typically advised.


Q: Is Bigital suitable for people with pre-existing kidney issues?

Official guidance includes specific dosage limitations for the Bisoprolol component of Bigital for individuals with severe renal impairment (a serious decrease in kidney function). For individuals with less severe kidney concerns, official product information suggests that use may require specific caution.


Q: Does taking Bigital require regular blood tests?

Routine blood tests are not universally required for all patients taking Bigital. However, mandatory therapeutic monitoring, which may include blood tests, is detailed when Bigital is used simultaneously with certain other medications, such as strong CYP3A4 inhibitors. Additional monitoring may also be advised for patients with existing conditions like diabetes.


Q: Does Bigital have a warning about stopping it abruptly?

Yes, official labeling contains a warning advising against the abrupt cessation of the Bisoprolol component, particularly in patients with underlying coronary artery disease. Regulatory guidelines describe that a process of gradual dose reduction (tapering) is typically required to avoid the potential temporary worsening of the patient's cardiac condition, such as increased chest pain.


Q: How quickly can someone expect Bigital to start working?

Bigital's components are designed to provide a 24-hour effect after each once-daily dose. While one component reaches its highest concentration in the blood within 6 to 12 hours, achieving the final goal of blood pressure control may take several weeks to a few months of continuous use.


Q: Is Bigital considered a long-term treatment?

Yes, Bigital is specifically indicated and officially approved by regulatory bodies for the long-term management of high blood pressure, also known as Essential Hypertension.


Q: Does Bigital show up on standard drug tests?

The components of Bigital (Amlodipine and Bisoprolol) are not classified as controlled substances and do not typically screen positive on standard common drug tests. However, the Bisoprolol component is included on the Prohibited List of the World Anti-Doping Agency (WADA) for certain competitive sports.


Q: Are there any foods or drinks to avoid while taking Bigital?

Official documentation specifies that Grapefruit or Grapefruit Juice must be avoided. This is because consuming grapefruit is described as potentially increasing the exposure to the Amlodipine component in the body.


Q: Can Bigital cause unusual changes in mood or behavior?

Reported side effects include common effects such as dizziness and less common effects like insomnia (difficulty sleeping). Official labeling for the Bisoprolol component also notes potential effects related to the Central Nervous System.


Q: Is Bigital safe to use while breastfeeding?

Official regulatory guidance states that Bigital is not recommended during breastfeeding. This position reflects that use is not recommended due to a lack of established safety data. It is not known whether the medication’s components are excreted in human milk.


Q: Is it true that Bigital can cause weight changes?

Regulatory documentation for the individual components lists unusual weight gain as an uncommon side effect in some patients. This effect is often associated with the potential for fluid retention, which can sometimes occur with this type of medication.


Q: Do older adults need a special evaluation before using Bigital?

Use of Bigital in older adults is generally permitted, but official documentation advises caution due to the natural decline in organ function that comes with age. While special tests are not always required solely based on age, careful monitoring is generally advised in the context of the product information.


Q: How does Bigital get cleared from the body?

The drug is cleared from the body through dual pathways. The Amlodipine component is largely broken down by the liver and then primarily removed by the kidneys. The Bisoprolol component is cleared by both the liver and the kidneys.


Q: Are there generic versions of Bigital available?

The individual medicines that make up Bigital—Amlodipine and Bisoprolol—are widely available as generics. The fixed-dose combination itself, where approved and available, is subject to regulatory testing to confirm that generic versions are comparable to the brand-name product.


Q: What does the research say about Bigital's effect on sleep?

Official safety data lists insomnia (difficulty sleeping) as an uncommon adverse reaction. This means it was reported in a small percentage (between 0.1% and 1%) of patients during clinical trials.


Q: Can Bigital be taken with vitamins or herbal supplements?

Official precautions state that a healthcare professional should be informed about all prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products being used. Specific caution is noted for certain herbal products, such as St John's wort, which is thought to affect how one of the drug's components is handled by the body.


Q: Can Bigital affect fertility?

Non-clinical studies, which use animal models, did not show that Bigital's components impaired fertility at high doses. However, the official product information notes that the effect of Bigital on human fertility has not been fully established.


Q: What is the difference between Bigital and a placebo in studies?

Clinical trials showed that Bigital was significantly more effective than a placebo (an inactive substance) at controlling blood pressure. The fixed-dose combination was demonstrated to be superior to placebo in blood pressure control.


Q: Is Bigital considered habit-forming or addictive?

Regulatory agencies do not classify the medication as controlled, and it is not described as habit-forming or addictive.


Q: Does Bigital interact with alcohol?

Official warnings state that consuming alcohol may have an additive effect in lowering blood pressure when taking Bigital. This combination could potentially increase side effects such as headache, dizziness, and lightheadedness.


Q: What is the half-life of Bigital?

Bigital is a combination drug, and its components have different half-lives (the time it takes for half the drug to be eliminated from the body). Amlodipine has a long half-life of approximately 35 to 50 hours, while Bisoprolol has a shorter half-life ranging from 10 to 12 hours.


Q: Why do some people feel dizzy after starting Bigital?

Dizziness is officially documented as a common side effect, often reported more frequently when treatment begins. This is an expected effect with blood pressure medications, as Bigital works to widen blood vessels and decrease the heart's workload, resulting in a reduction in blood pressure.


Q: Is Bigital a hormone-based medication?

No, Bigital is officially classified as an antihypertensive agent. Its active components are a Calcium Channel Blocker (Amlodipine) and a Beta-blocker (Bisoprolol), neither of which is a hormone.


Q: Can Bigital worsen anxiety?

While anxiety is not explicitly listed as a common side effect, official regulatory documents report related neurological effects. These include dizziness and insomnia, which are effects that may be monitored closely in individuals prone to anxiety.

How should Bigital be stored and disposed of?

How to Store and Dispose of Bigital

Storage Requirements

Official regulatory guidelines require Bigital tablets to be stored at a controlled room temperature, below 25 C (77 F). The medicine must not be refrigerated or frozen, as this can affect product stability. For protection, the tablets must be kept in the original container, shielded from both light and moisture. A mandatory storage requirement is to Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Bigital tablets must be managed as pharmaceutical waste. Official labeling mandates that the product must not be discarded in household trash or via wastewater (such as flushing down a toilet) due to environmental concerns. The approved procedure is to return the unused medication to an authorized collection point, such as a pharmacy or local drug take-back program, for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bigital found in:

A-Z Index: